CGM market surges as coverage expands beyond insulin users

The October 2026 inflection point in CGM did not emerge from a standing start; it rested on a coverage architecture that had already been reset by CMS in 2021. By eliminating the requirement that beneficiaries keep doing finger-stick self-monitoring to qualify for CGM, CMS removed what it described as the “contradiction of requiring finger sticks to qualify for a device designed to reduce finger-stick dependence,” creating the regulatory baseline that later made broader adoption beyond insulin-dependent use cases administratively and politically feasible.

That earlier CMS decision matters to the October 2026 story because pivotal trial readouts, regulatory clearances, and payer agreements only translate into real uptake when coverage rules no longer block access at the front door. Once the finger-stick prerequisite was gone, the system had a workable template for reimbursing CGM on the basis of clinical utility rather than legacy testing habits, helping convert 2026’s evidence and deal activity into a credible pathway for expansion to a much larger population than the traditional insulin-dependent base.

Clinical validation now rests on randomized evidence, not just anecdote. As Better Bioeconomy reported from Dexcom’s June presentation at the American Diabetes Association meeting, the CONNECT trial randomised 283 adults with type 2 diabetes who were not on insulin across 22 US primary care practices for 26 weeks, and “the monitored group’s HbA1c fell 1.6 points against 0.7 in the control group,” showing that CGM-based monitoring delivered a measurable improvement versus routine finger-prick care in a non-insulin population.

That matters because HbA1c captures average blood sugar over roughly the prior three months, making the 26-week endpoint evidence of sustained glucose improvement rather than a one-off reading. Medical Device and Diagnostic industry analysis said Dexcom’s CONNECT cohort included 265 patients who “weren't using insulin,” starting from an average A1C of 8.8%, and framed the outcome as proof CGM “works” for a largely overlooked type 2 population; CEO Jake Leach said the successful results “reinforce our confidence in the path ahead and position us well to deliver on our long-range plan.”

The kidney-health case for CGM now rests on more than theory: Kaiser Permanente Division of Research reported that, in a large 3-year study of high-risk type 2 diabetes patients published in JAMA Network Open, continuous glucose monitor use was associated with early kidney-health improvement signals, not just better glucose control. In that quasi-trial design, researchers used the urine albumin to creatinine ratio, which measures the amount of protein the kidneys spill into the urine, and found that patients with poorly controlled type 2 diabetes who used monitors had less protein in their urine by the end of follow-up—an early indication their kidneys were in better health.

That signal carries weight because it came from a high-risk cohort and a structured comparison over time: the Kaiser Permanente Northern California Diabetes Registry study included 25,648 patients and compared the 2,771 patients who started using a continuous glucose monitor with those who did not, using a statistical method designed to emulate a randomized controlled trial while tracking kidney outcomes over 3 years. Separate support came from a New Zealand-led comparative study in high-risk type 2 diabetes patients on intensive insulin therapy, which compared real-time CGM with traditional finger-prick testing and projected fewer long-term complications including kidney disease; notably, avoiding a single case of end-stage renal disease could fund CGM use for 37 years.

The market unlock is happening not just because CGM is clinically credible, but because payers now have a reimbursement-ready operating model for broader type 2 populations. FinancialContent reported that Nsight Health’s glucose-monitoring patients who stayed active for 12 to 18 months saw an average blood glucose reduction of 71.6 mg/dL, while between January and June 2026 its clinical staff reviewed and actioned 10.9 million remote monitoring alerts and cleared 1.3 million high-acuity cases; out-of-range readings trigger direct nurse outreach, and the company positions its programs as CMS-reimbursed RPM, CCM and PCM offerings, indicating a coverage pathway that can extend monitoring access to additional type 2 patients.

That operating proof is now being matched by explicit coverage expansion. The Earnings Debate said Dexcom’s partnership with Prime Therapeutics is designed to bring commercial coverage to over 7 million type 2 non insulin lives by year-end, expanding CGM access to millions of type 2 patients who are not on insulin and enlarging the covered market beyond the company’s historical core, with CEO Jake Leach saying coverage should reach all people with diabetes; the same analysis called the repeated focus on type 2 non insulin a classic corporate pivot, away from the old core of type 1 and intensive-insulin users, while FinancialContent noted Optum estimated roughly $2,500 to $3,000 per member per year in pre-reimbursement medical savings for Medicare fee-for-service patients 65+.